BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 36255654)

  • 1. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Guo B; Wang Y; Liu W; Zhang S
    Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifies microtubule-binding protein
    Wang W; Zhang J; Wang Y; Xu Y; Zhang S
    Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.
    Li L; Feng Q; Wang X
    Comput Struct Biotechnol J; 2020; 18():668-675. PubMed ID: 32257050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.
    Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C
    Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA.
    Ye B; Shi J; Kang H; Oyebamiji O; Hill D; Yu H; Ness S; Ye F; Ping J; He J; Edwards J; Zhao YY; Guo Y
    RNA Biol; 2020 Nov; 17(11):1666-1673. PubMed ID: 31607216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis.
    Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T
    Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
    Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
    Front Immunol; 2022; 13():903461. PubMed ID: 35663977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of the novel omicron receptor AXL in cancers.
    Zhang WN; Li XP; Wang PF; Zhu L; Xiao XH; Dai YJ
    Comput Struct Biotechnol J; 2022; 20():3304-3312. PubMed ID: 35782741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
    Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
    Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rewired functional regulatory networks among miRNA isoforms (isomiRs) from let-7 and miR-10 gene families in cancer.
    Liang T; Han L; Guo L
    Comput Struct Biotechnol J; 2020; 18():1238-1248. PubMed ID: 32542110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer.
    Wang Y; Zhang Y; Wang F; Li T; Song X; Shi H; Du J; Zhang H; Jing H; Han J; Tong D; Zhang J
    Sci Rep; 2022 Nov; 12(1):18518. PubMed ID: 36323715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatics and survival analysis of glia maturation factor-γ in pan-cancers.
    Lan A; Ren C; Wang X; Tong G; Yang G
    BMC Cancer; 2021 Apr; 21(1):423. PubMed ID: 33863293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 19. Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3.
    Ling ZN; Hong LL; Wu J; Ling ZQ
    Sci Rep; 2024 Feb; 14(1):3030. PubMed ID: 38321173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.
    Ball MW; Gorin MA; Drake CG; Hammers HJ; Allaf ME
    Eur Urol Focus; 2017 Dec; 3(6):584-589. PubMed ID: 28753846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.